The persistent medicinal cannabis stigma continues to pose a significant challenge for patients seeking legitimate therapeutic options, with recent findings from New Zealand indicating that a substantial majority of patients still perceive this societal barrier. According to Dr. Waseem Alzaher, chief executive of The Cannabis Clinic, improving understanding is crucial for patients to access safe and informed care, as reported by RNZ.
Addressing Medicinal Cannabis Stigma
A survey conducted last year by The Cannabis Clinic, involving 1000 patients, revealed that 65 percent of respondents felt stigma was associated with medicinal cannabis. Dr. Alzaher highlighted that this perception extends “even within the medical community,” underscoring the need for greater education and open dialogue.
The Patient Experience and Access Pathways
For many patients, this medicinal cannabis stigma can create a considerable burden, particularly for those who might otherwise seek cannabis illegally due to a lack of accessible information or fear of judgment. Dr. Alzaher noted that providing a professional service aims to offer a safe space for these conversations, ensuring that individuals who may benefit from prescribed cannabis can do so without fear or legal concern.
- Reduced Quality of Life: Patients suffering from conditions that may be alleviated by medicinal cannabis often experience a reduced quality of life, and stigma can add another layer of distress.
- Legal Concerns: Individuals accessing cannabis illegally carry the burden of potential legal repercussions, which can be alleviated by access to regulated prescription pathways.
- Informed Care: A professional clinical setting allows for proper medical assessment, dosage guidance, and monitoring of potential adverse effects, which is not possible with unregulated access.
The goal is to ensure that patients who could benefit from medicinal cannabis are not deterred by outdated perceptions but are instead supported through established medical channels.
Treating Medicinal Cannabis as a Prescribed Medicine
Dr. Alzaher emphasised that medicinal cannabis should be regarded as any other prescribed medicine. He stated, “It has its right time, place, person, dose – and anything, including non-pharmaceuticals, have risks of adverse effects – so let’s not take cannabis outside of that perspective.” This perspective aligns with the regulatory frameworks in countries like New Zealand, where it is a prescribable medicine.
The call for more education around medicinal cannabis is central to dismantling these enduring perceptions. By fostering a more informed environment, both within the general public and among healthcare professionals, the aim is to ensure that patients can discuss their treatment options openly and access appropriate care without facing undue judgment or societal barriers. This approach supports the ongoing integration of cannabinoid therapies into modern medicine, building on earlier coverage of medical cannabis awareness.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
